Fred Alger Management’s Trevi Therapeutics TRVI Stock Holding History

Fred Alger Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	+66,490	New	+$967K	﹤0.01%	352
2026 Q1	–	Sell	-157,980	Closed	-$1.98M	–	513
2025 Q4	$1.98M	Sell	157,980 -33,065	-17%	-$382K	0.01%	315
2025 Q3	$1.75M	Buy	191,045 +131,620	+221%	+$987K	0.01%	330
2025 Q2	$325K	Sell	59,425 -17,274	-23%	-$107K	﹤0.01%	398
2025 Q1	$482K	Buy	+76,699	New	+$366K	﹤0.01%	366
2024 Q4	–	Sell	-76,544	Closed	-$256K	–	474
2024 Q3	$256K	Buy	+76,544	New	+$228K	﹤0.01%	398

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Fred Alger Management's TRVI Position: Q2 2026 in Review

Fred Alger Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 66,490 shares worth $1.24M. The stake represents ﹤0.01% of the portfolio and ranks #352 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in TRVI as recently as Q4 2025.

Fred Alger Management first reported a position in TRVI in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.98M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Fred Alger Management held 66,490 shares of Trevi Therapeutics worth $1.24M as of Q2 2026.
Trevi Therapeutics was a new Fred Alger Management position in Q2 2026.
Trevi Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q2 2026, its #352 holding.
Fred Alger Management first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 6 quarters since.
Fred Alger Management's Trevi Therapeutics position peaked at $1.98M in Q4 2025.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.